North China Pharmaceutical: Its subsidiary, Huasheng Company, received the "Approval Notice for the Listing of the Chemical Raw Material Drug Sacubitril/Valsartan Sodium"

North China Pharmaceutical announced that its wholly controlled subsidiary, Huasheng Company, has received the “Notice of Approval for the Listing of the Chemical Active Pharmaceutical Ingredient (API) for Sacubitril/Valsartan Sodium” issued by the National Medical Products Administration.

Sacubitril/Valsartan Sodium is a medication for the treatment of chronic heart failure. Its tablets are used for adult patients with chronic heart failure with reduced ejection fraction (NYHA II–IV, LVEF ≤ 40%), reducing the risk of cardiovascular death and hospitalization due to heart failure. In addition, the Sacubitril/Valsartan Sodium tablets can replace angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB), and are used in combination with other heart failure treatment medications.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin